These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3068036)

  • 21. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of octreotide in patients with cirrhosis and portal hypertension; relationship between the plasma levels of the analogue and the magnitude and duration of the reduction in corrected wedged hepatic venous pressure.
    Jenkins SA; Nott DM; Baxter JN
    HPB Surg; 1998; 11(1):13-21. PubMed ID: 9830576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Octreotide suppresses both growth hormone (GH) and GH-releasing hormone (GHRH) in acromegaly due to ectopic GHRH secretion.
    Moller DE; Moses AC; Jones K; Thorner MO; Vance ML
    J Clin Endocrinol Metab; 1989 Feb; 68(2):499-504. PubMed ID: 2493033
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Octreotide for acromegaly treatment: a reappraisal.
    Giustina A; Karamouzis I; Patelli I; Mazziotti G
    Expert Opin Pharmacother; 2013 Dec; 14(17):2433-47. PubMed ID: 24124691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
    Pokuri VK; Fong MK; Iyer R
    Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.
    Degen L; Beglinger C
    Digestion; 1999; 60 Suppl 2():9-14. PubMed ID: 10207226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The interrelationship between the anti-mitotic action of the somatostatin analog octreotide and that of cytostatic drugs and suramin.
    Lamberts SW; van Koetsveld P; Hofland LJ
    Int J Cancer; 1991 Jul; 48(6):938-41. PubMed ID: 1860738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
    Graillon T; Romano D; Defilles C; Saveanu A; Mohamed A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A
    J Neurosurg; 2017 Sep; 127(3):660-669. PubMed ID: 27982767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of the long-acting somatostatin analogue octreotide (SMS 201-995) in acromegaly.
    Nicholls J; Wynick D; Domin J; Sandler LM; Bloom SR
    Clin Endocrinol (Oxf); 1990 May; 32(5):545-50. PubMed ID: 2364560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthetic somatostatin analog (octreotide) suppresses daytime growth hormone secretion equivalently in young and older men: preserved pituitary responsiveness to somatostatin's inhibition in aging.
    Mulligan T; Jaen-Vinuales A; Godschalk M; Iranmanesh A; Veldhuis JD
    J Am Geriatr Soc; 1999 Dec; 47(12):1422-4. PubMed ID: 10591235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From somatostatin to Sandostatin: pharmacodynamics and pharmacokinetics.
    Marbach P; Briner U; Lemaire M; Schweitzer A; Terasaki T
    Digestion; 1993; 54 Suppl 1():9-13. PubMed ID: 8103016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Future medical prospects for Sandostatin.
    Harris AG
    Metabolism; 1990 Sep; 39(9 Suppl 2):180-5. PubMed ID: 2205787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacodynamic analysis of octreotide in acromegalic patients.
    Comets E; Mentré F; Grass P; Kawai R; Marbach P; Vonderscher J
    Clin Pharmacol Ther; 2003 Jan; 73(1):95-106. PubMed ID: 12545148
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin analogs for cancer treatment and diagnosis: an overview.
    Scarpignato C; Pelosini I
    Chemotherapy; 2001; 47 Suppl 2():1-29. PubMed ID: 11275699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
    Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
    Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects.
    Gardner-Roehnelt NM
    Clin J Oncol Nurs; 2012 Feb; 16(1):56-64. PubMed ID: 22297008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
    Gorden P; Comi RJ; Maton PN; Go VL
    Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacodynamic effects of Sandostatin in the gastrointestinal tract.
    Gyr KE; Meier R
    Digestion; 1993; 54 Suppl 1():14-9. PubMed ID: 8103010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients.
    van Thiel SW; Romijn JA; Biermasz NR; Ballieux BE; Frölich M; Smit JW; Corssmit EP; Roelfsema F; Pereira AM
    Eur J Endocrinol; 2004 Apr; 150(4):489-95. PubMed ID: 15080778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.